Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
Why are caffeine, nicotine, energy drinks and prescription stimulants largely accepted, socially and legally, while other psychoactive plants, mushrooms and substances are in part banned or criminalized? That is the question taken up by the conceptual paper “Stimulants, Psychoactive Plants, and Human Optimization: Medical Gatekeeping, Prohibition, and Adult Autonomy in Drug Policy”.
The author argues that the regulation of psychoactive substances is not determined by their pharmacological risks alone. Cultural familiarity, medical approval and gatekeeping, economic and fiscal interests, social rituals, historical and religious or moral influences, and state and institutional interests all play a part as well.
As an example of this unequal regulatory treatment, the paper points to various socially established forms of activation and performance enhancement. Alongside coffee, tea and caffeine, these include nicotine, energy drinks, pre-workout products, prescription stimulants, so-called wakefulness-promoting agents and various cognitive enhancers. Other forms of self-determined use of psychoactive plants, mushrooms or compounds outside recognized medical or commercial structures are, by contrast, often stigmatized, restricted or criminalized.
The author introduces the term “self-directed activation and optimization”. It refers to self-determined attempts by adults to change their energy, attention, motivation, endurance, emotional state, social functioning or cognitive abilities. In doing so, he distinguishes pharmacological stimulants from the broader category of means and practices used for activation and optimization.
The paper does not fundamentally question that psychoactive substances can be regulated. In the author’s view, potential for dependence, cardiovascular risks, psychiatric vulnerability, dosage and route of administration, dangerous combinations and risks for adolescents could justify measures such as education, labeling, quality control, transparent product information, regulated access or targeted restrictions.
He does, however, see a particular burden of justification where the personal use of adults is criminalized. A criminal prohibition would have to rest on concrete harms or other weighty reasons. Those named include harm to third parties, coercion, deception, endangerment of minors, unsafe forms of commercialization or the demonstrated failure of less restrictive measures.
To assess different substances and products, the author proposes a “Liberty, Harm, and Intervention Threshold Test”. Among the factors it would take into account are mechanism of action, dose, route of administration, preparation and product safety, developmental risks, possible harm to third parties, interactions, social pressure to perform, cultural biases, medical double standards and the proportionality of state intervention.
The paper thus argues for a drug policy that distinguishes more clearly between concrete harm, the right to self-determination, unsafe markets, and the pressure to perform created socially or by outside influence. Instead of a prohibition shaped primarily by moral judgment, the author proposes a proportionate approach in which the strength of state intervention is matched to the specific risks and harms at hand.
The contribution is a conceptual and legal-policy argument, not an empirical study. It therefore does not offer empirical proof that particular legal and illegal substances are equally dangerous. Its central subject is rather the question of the criteria by which different forms of psychoactive activation and performance enhancement should be treated in law.
